Table 3.
Improvements in health‐related quality of life and productivity at week 256a
| Golimumab + MTX | ||||||
|---|---|---|---|---|---|---|
| Placebo + MTX | Golimumab 100 mg + placebo | 50 mg | 100 mg | Combined | Total | |
| SF‐36 PCS score | ||||||
| Improvement from baseline, mean ± SD | 11.3 ± 10.5 | 11.6 ± 11.0 | 11.9 ± 11.1 | 11.9 ± 10.0 | 11.9 ± 10.6 | 11.7 ± 10.7 |
| Patients with score ≥50, no. (%) | 28 (25.7) | 28 (26.9) | 33 (30.6) | 28 (28.3) | 61 (29.5) | 117 (27.9) |
| SF‐36 MCS score | ||||||
| Improvement from baseline, mean ± SD | 4.5 ± 12.6 | 7.6 ± 12.0 | 5.7 ± 12.1 | 6.4 ± 11.9 | 6.1 ± 12.0 | 6.0 ± 12.2 |
| Patients with score ≥50, no. (%) | 47 (43.1) | 51 (49.0) | 55 (50.9) | 44 (44.4) | 99 (47.8) | 197 (46.9) |
| Improvement in the impact of disease on productivity, mean ± SD | 3.2 ± 3.1 | 4.3 ± 4.3 | 3.9 ± 2.7 | 4.2 ± 2.8 | 4.0 ± 2.8 | 3.9 ± 3.3 |
a
MTX = methotrexate; SF‐36 = Short Form 36 health survey; PCS = physical component summary; MCS = mental component summary.